Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02650648
Title Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

neuroblastoma

Therapies

Aldesleukin + Cyclophosphamide + Naxitamab

Age Groups: child | senior | adult
Covered Countries USA


No variant requirements are available.